주식/증권 📈 긍정적

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?

Yahoo Finance 2026/08/14 17:15:00 8회

요약

ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.

원문 기사 보기

관련 뉴스

NANO Nuclear, Hyundai Engineering sign MoU for Kronos MMR reactor project

Western Asset Global High Income Fund reports results for the quarter ending on August 31

HPE integrates EdgeConnect with Mist and Aruba Central for AI-driven networking

Stock Market Today: Nasdaq Up As Fed Meet Starts; Boeing Shares Tumble On Earnings Miss (Live Coverage)

뉴스 목록으로